Sign up
Pharma Capital

Motif Bio PLC buoyed by early-stage data pointing to new indication for lead drug

The update, provided at a conference called IDWeek 2017, follows on from the successful phase III clinical trial of the drug
lung x-ray
iclaprim could be used to treat cystic fibrosis patients with staphylococcus aureus pneumonia

Motif Bio Plc (LON:MTFB) said new pre-clinical data point to potential efficacy of a lead drug to treat cystic fibrosis sufferers who have contracted staphylococcus aureus pneumonia.

The update, provided at a conference called IDWeek 2017, follows on from the successful phase III clinical trial of the drug for people with acute bacterial skin and skin structure infections (ABSSSI).

WATCH: Motif Bio on track to move forward with new drug application after Iclaprim success

Researchers found there was a 100% survival rate among rats with the infection that were treated with Motif’s iclaprim antibiotic. The drug also helped suppress toxin production.

iclaprim has been granted orphan drug status for the treatment of cystic fibrosis patients with staphylococcus aureus pneumonia, which means the medication could qualify for various development incentives including tax credits.

“Staphylococcus aureus is a common cause of pneumonia in patients with cystic fibrosis and we do not believe that any antibiotic has been approved for this indication,” said David Huang, the chief medical officer of Motif.

WATCH: The 'end of the marathon' for Motif Bio's Iclaprim

“Some 80% or more of patients with cystic fibrosis die as a result of respiratory infections caused by a variety of bacteria, and MRSA infections have been growing in recent years. 

“The encouraging new data presented today support developing iclaprim as a potential treatment option for MRSA infections in patients with cystic fibrosis, and iclaprim was recently granted orphan drug designation in the US for Staphylococcus aureus lung infections in this patient group." 

View full MTFB profile

Motif Bio Plc Timeline

Article

Motif Bio : The home plate beckons

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.